OBJECTIVE: This systematic review aims to outline and summarize known tumor-associated antigens (TAAs) or anti-TAA autoantibodies and their diagnostic values in ovarian cancer (OC). METHODS: A systematic literature search was conducted in two databases. Data were independently extracted and reviewed by two junior investigators and the disagreement was further resolved by consulting one of the senior investigators. RESULTS: Sixty publications reporting 113 different TAAs or anti-TAA autoantibodies were included. The majority of the studies were conducted in western countries. CA125, p53 and HE4 were the most frequently tested TAAs in OC. Meta-analysis showed that there was a significant association between serum anti-p53 autoantibody and increased risk of OC. CONCLUSION: Serum TAAs or anti-TAA autoantibodies are promising diagnostic biomarkers in the detection of OC. A customized mini-array of multiple TAAs may enhance the detection of anti-TAA autoantibodies in OC. Additional studies with sufficient number of OC patients and carefully selected controls are needed to further verify the results.
OBJECTIVE: This systematic review aims to outline and summarize known tumor-associated antigens (TAAs) or anti-TAA autoantibodies and their diagnostic values in ovarian cancer (OC). METHODS: A systematic literature search was conducted in two databases. Data were independently extracted and reviewed by two junior investigators and the disagreement was further resolved by consulting one of the senior investigators. RESULTS: Sixty publications reporting 113 different TAAs or anti-TAA autoantibodies were included. The majority of the studies were conducted in western countries. CA125, p53 and HE4 were the most frequently tested TAAs in OC. Meta-analysis showed that there was a significant association between serum anti-p53 autoantibody and increased risk of OC. CONCLUSION: Serum TAAs or anti-TAA autoantibodies are promising diagnostic biomarkers in the detection of OC. A customized mini-array of multiple TAAs may enhance the detection of anti-TAA autoantibodies in OC. Additional studies with sufficient number of OC patients and carefully selected controls are needed to further verify the results.
Entities:
Keywords:
autoantibody; biomarker; cancer screening; early diagnosis; ovarian cancer; tumor-associated antigen
Authors: Frank Antony; Cecilia Deantonio; Diego Cotella; Maria Felicia Soluri; Olga Tarasiuk; Francesco Raspagliesi; Fulvio Adorni; Silvano Piazza; Yari Ciani; Claudio Santoro; Paolo Macor; Delia Mezzanzanica; Daniele Sblattero Journal: Oncoimmunology Date: 2019-06-04 Impact factor: 8.110
Authors: Benjamin A Katchman; Diego Chowell; Garrick Wallstrom; Allison F Vitonis; Joshua LaBaer; Daniel W Cramer; Karen S Anderson Journal: Gynecol Oncol Date: 2017-04-18 Impact factor: 5.482
Authors: Renée T Fortner; Helena Schock; Charlotte Le Cornet; Anika Hüsing; Allison F Vitonis; Theron S Johnson; Raina N Fichorova; Titilayo Fashemi; Hidemi S Yamamoto; Anne Tjønneland; Louise Hansen; Kim Overvad; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Gianluca Severi; Heiner Boeing; Antonia Trichopoulou; Eleni-Maria Papatesta; Carlo La Vecchia; Domenico Palli; Sabina Sieri; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; N Charlotte Onland-Moret; Petra H Peeters; H B As Bueno-de-Mesquita; Elisabete Weiderpass; J Ramón Quirós; Eric J Duell; Maria-Jose Sánchez; Carmen Navarro; Eva Ardanaz; Nerea Larrañaga; Björn Nodin; Karin Jirström; Annika Idahl; Eva Lundin; Kay-Tee Khaw; Ruth C Travis; Marc Gunter; Mattias Johansson; Laure Dossus; Melissa A Merritt; Elio Riboli; Kathryn L Terry; Daniel W Cramer; Rudolf Kaaks Journal: Int J Cancer Date: 2017-12-11 Impact factor: 7.396
Authors: Wei-Lei Yang; Zhen Lu; Jing Guo; Bryan M Fellman; Jing Ning; Karen H Lu; Usha Menon; Makoto Kobayashi; Samir M Hanash; Joseph Celestino; Steven J Skates; Robert C Bast Journal: Cancer Date: 2019-11-12 Impact factor: 6.860
Authors: Robert C Bast; Zhen Lu; Chae Young Han; Karen H Lu; Karen S Anderson; Charles W Drescher; Steven J Skates Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-10-13 Impact factor: 4.254